A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.

Authors

Sarmad Sadeghi

Norris Comprehensive Cancer Center, Los Angeles, CA

Sarmad Sadeghi , Melissa Plets , Primo N Lara Jr., Catherine Tangen , Rick Bangs , Seth P. Lerner , Thomas W. Flaig , Daniel P. Petrylak , Ian M Thompson Jr.

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A phase III randomized trial of eribulin (E) with or without gemcitabine versus standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.

First Author: Sarmad Sadeghi

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).

First Author: Matt D. Galsky

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.

First Author: Srikala S. Sridhar

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Real-world treatment patterns and clinical outcomes among patients with metastatic urothelial carcinoma.

First Author: Daniel M. Geynisman